2019 Looks Bright, SD-101 should send stocks soaring
Dynavax recently presented a company outlook for 2019 at the JP Morgan Healthcare Conference. During the presentation, CEO Eddie Gray revealed encouraging HEPISLAV-B sales for Q4 of ~3.7M.
2018 was a big year for Dynavax's lead immuno-oncology candidate SD-101. The company has stated they are looking for a potential partner for their planned Phase III in melanoma.
The stock experienced a strong sell-off in Q4, but the new year should treat DVAX well.
In its March 2019 Cowen presentation, Dynavax issued a pipeline slide. Although I note a lack of phase 3 candidates. It has but a single therapy, SD-101, in phase 2 that it is advancing in combination with Merck's Keytruda (pembrolizumab) in various combinations.
Positive news from SD-101 should send stocks soaring.
2018 was a big year for Dynavax's lead immuno-oncology candidate SD-101. The company has stated they are looking for a potential partner for their planned Phase III in melanoma.
The stock experienced a strong sell-off in Q4, but the new year should treat DVAX well.
In its March 2019 Cowen presentation, Dynavax issued a pipeline slide. Although I note a lack of phase 3 candidates. It has but a single therapy, SD-101, in phase 2 that it is advancing in combination with Merck's Keytruda (pembrolizumab) in various combinations.
Positive news from SD-101 should send stocks soaring.
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.